{"description":"\"0\" Total Number of Participants at Risk (e.g.., other \\[non-serious\\] adverse events were not collected or assessed as part of the study).","eventGroups":[{"description":"Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":11,"title":"Regimen A"},{"description":"Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..","id":"EG001","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":4,"title":"Regimen B-1"},{"description":"Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.","id":"EG002","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":1,"seriousNumAtRisk":3,"title":"Regimen B-2"},{"description":"Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.","id":"EG003","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":2,"seriousNumAtRisk":4,"title":"Regimen B-3"},{"description":"Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.","id":"EG004","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":2,"seriousNumAtRisk":10,"title":"Regimen C"},{"description":"Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.","id":"EG005","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"Regimen D"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Melena/GI bleeding"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Elevated Bilirubin associated with graft versus host disease (GVHD)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Memory loss"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Edema"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Stomatitis/pharyngitis (oral/pharyngeal mucositis)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Mood alteration-anxiety, agitation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Pleural effusion (non-malignant)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Rash/dermatitis associated with high-dose chemotherapy or BMT studies."},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Hematuria"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":4},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Death not associated with CTCAE term - Multi-organ failure"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Hypertension"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":0,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Confusion"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":1,"numAtRisk":4},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Dyspnea (shortness of breath)"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (2.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":3},{"groupId":"EG003","numAffected":0,"numAtRisk":4},{"groupId":"EG004","numAffected":1,"numAtRisk":10},{"groupId":"EG005","numAffected":0,"numAtRisk":2}],"term":"Hypoxia"}],"timeFrame":"Adverse events were collected while patients were on study over a an eleven year period. Only grade 3 and above toxicity were collected."}